Cryoport, INC

Cryoport, Inc. held its 2026 Annual Meeting, confirming director elections, auditor ratification, and the approval of an amendment to its 2018 Omnibus Equity Incentive Plan.

Cryoport announced first quarter 2026 financial results, with total revenue up 16% year-over-year to $47.8 million, and raised its full-year revenue guidance.

Cryoport, Inc. announced strong financial results for Q4 and full-year 2025, surpassing revenue guidance and projecting continued growth for 2026.

Cryoport, Inc. reported a 15% year-over-year revenue increase to $44.2 million for Q3 2025 and raised its full-year 2025 revenue guidance to $170-$174 million.

Cryoport, Inc. reported strong second quarter 2025 financial results with a 14% year-over-year revenue increase and a significant capital infusion from the CRYOPDP divestiture and DHL partnership.

Cryoport, Inc. has completed the divestiture of its CRYOPDP business to DHL Group for approximately $200 million in cash and established a strategic partnership to enhance global life sciences supply chain solutions.

Cryoport, Inc. announced its first quarter 2026 financial results, showcasing a 16.5% increase in total revenue driven by strong performance in both its Life Sciences Services and Life Sciences Products segments.

Cryoport, Inc. reported a 15.4% increase in total revenue for the third quarter of 2025, driven by strong demand in life sciences services and products, alongside a significant gain from the divestiture of its CRYOPDP business.

Cryoport, Inc. reports a significant swing to net income in Q2 2025, driven by the strategic divestiture of its CRYOPDP business and strong growth in core life sciences services.

Cryoport, Inc. announces its Q1 2025 financial results, including revenue growth and a strategic decision to divest its CRYOPDP business to DHL.

Cryoport's Q3 2024 results show a slight revenue increase, offset by a significant impairment charge and strategic debt repurchases.

Cryoport's Q2 2024 results show a net loss due to a significant goodwill impairment, despite a slight increase in overall revenue.

Cryoport, Inc. reported a 12.4% increase in total revenue to $176.2 million for fiscal year 2025, driven by strong demand in life sciences services and products, alongside the strategic divestiture of its CRYOPDP business.

Cryoport's 2024 results reveal a slight revenue decrease alongside strategic cost management and significant non-cash impairment charges.

Cryoport's 2023 annual report highlights strategic acquisitions, global expansion, and a focus on cell and gene therapy supply chain solutions, while also addressing challenges such as decreased product revenue and a goodwill impairment.

Chief Digital and Tech Officer Edward J. Zecchini exercised options and sold 35,000 shares of Cryoport, Inc. common stock.

Cryoport, Inc. Director Linda Baddour acquired 10,350 shares of common stock and was granted options for 16,077 shares.

Cryoport, Inc. Chief Financial Officer Robert Stefanovich sold 169,427 shares of common stock on June 4, 2026.

Director Daniel M. Hancock acquired 10,350 shares of restricted stock and 16,077 stock options in Cryoport, Inc.

Director Robert J. Hariri acquired 10,350 shares of restricted stock and 16,077 stock options in Cryoport, Inc.

Cryoport, Inc. Director Ramkumar Mandalam reported the acquisition of restricted stock and the sale of common shares in a recent SEC Form 4 filing.

Cryoport, Inc. announces its 2026 Annual Meeting of Stockholders to be held virtually on June 5, 2026, to address director elections, executive compensation, and equity plan amendments.

Cryoport, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Cryoport's 2025 proxy statement highlights a challenging 2024 due to macroeconomic conditions, but emphasizes strategic advancements and cost reduction initiatives.

Cryoport, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Cryoport is asking stockholders to approve an amendment to its 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares, citing company growth and the need to align employee incentives with stockholder value.

Several entities affiliated with Millennium Management have reported a combined beneficial ownership of 3.4% of Cryoport, Inc. common stock as of June 30, 2026.

The Vanguard Group has amended its Schedule 13G filing for CryoPort Inc, reporting 0% beneficial ownership due to an internal realignment where subsidiaries will now report separately.

Millennium Management and affiliated entities have disclosed a 6.5% beneficial ownership stake in Cryoport, Inc. common stock.

Brown Capital Management, LLC reported an increased beneficial ownership of 5.24% in Cryoport Inc.'s common stock as of September 30, 2025.

Millennium Management LLC and affiliated entities have reported a passive 5.1% beneficial ownership stake in Cryoport, Inc. common stock.

Alger Associates, Inc. has updated its passive ownership stake in Cryoport, Inc., reporting beneficial ownership of 4.7% of common stock.